Disclosure MH has reported honoraria from Novartis, Pfizer, priME Oncology, consulting or advisory role for AbbVie, Bayer Pharma AG, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis and Pfizer, research funding from Astellas, Bayer Pharma AG, BerGenBio, Daiichi Sankyo, Karyopharm, Novartis, Pfizer and Roche; YO has reported consulting or advisory role for Amgen, Novartis, AbbVie, Pfizer, Medison and Roche; NB has reported consulting or advisory role for Amgen, Bristol-Myers Squibb, Celgene, Jazz Pharmaceuticals, Novartis, Pfizer and Sanofi, research funding from Amgen, Bristol-Myers Squibb, Novartis and Jazz Pharmaceuticals; SBM has reported consulting or advisory role for Novartis and Celgene; CC has reported consulting or advisory role for AbbVie, Celgene, Daiichi-Sankyo, Jazz Pharmaceuticals and Novartis, research funding from Celgene; JJ has reported consulting or advisory role for AbbVie, Daiichi Sankyo, Incyte Corporation, Jazz Pharmaceuticals, Novartis and Pfizer, research funding from Bristol-Myers-Squibb, Daiichi Sankyo, Janssen Global Services, Jazz Pharmaceuticals, Novartis and Takeda Oncology; AW has reported consulting or advisory role for AbbVie, Celgene, Janssen, Jazz Pharmaceuticals, Novartis and Pfizer, research funding from Jazz Pharma; CB has reported research funding from Bayer, Roche and Janssen, honoraria from Roche, Janssen, AbbVie and Celgene.